AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Cogent Biosciences Raises Price Target to $22.00 by 83.33%
ByAinvest
Thursday, Jul 10, 2025 11:12 pm ET1min read
Cogent Biosciences (COGT) has received a positive analyst action from HC Wainwright & Co, reaffirming its "Buy" rating and raising the price target by 83.33% to $22.00. The average one-year price target for COGT is $17.00, with an upside of 80.08% from the current price. The average brokerage recommendation is 1.9, indicating an "Outperform" status.
Cogent Biosciences (COGT) has received a positive analyst action from HC Wainwright & Co, reaffirming its "Buy" rating and raising the price target by 83.33% to $22.00. The average one-year price target for COGT is $17.00, with an upside of 80.08% from the current price. The average brokerage recommendation is 1.9, indicating an "Outperform" status.The positive analyst action comes amidst encouraging news for COGT. The company's lead product candidate, bezuclastinib (CGT9486), has shown a statistically significant reduction in symptoms in patients with mastocytosis, a type of blood disorder. This development has raised the probability of approval for bezuclastinib in NonAdvSM to 95% from the prior 60%, according to HC Wainwright [1].
Other analysts have also shown optimism for COGT. Leerink Partners raised their price objective on COGT from $16.00 to $18.00 and gave the company an "outperform" rating [1]. Robert W. Baird increased their target price on COGT from $7.00 to $9.00 and gave the stock a "neutral" rating [1]. Jefferies Financial Group increased their target price on COGT from $23.00 to $28.00 and gave the stock a "buy" rating [1]. JPMorgan Chase & Co. raised their price objective on COGT from $21.00 to $25.00 and gave the stock an "overweight" rating [1].
The company's stock has seen an upward trend, with COGT trading up $0.13 during trading on July 2, 2025, reaching $9.48. The stock has a market cap of $1.08 billion, a PE ratio of -5.11, and a beta of 1.88 [1].
Investors should note that while COGT has seen positive analyst actions, it is essential to consider the broader market and the company's specific risks. As always, it is recommended to conduct thorough research and consult with a financial advisor before making investment decisions.
References:
[1] https://www.marketbeat.com/instant-alerts/cogent-biosciences-nasdaqcogt-price-target-raised-to-2200-2025-07-08/
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3T515S:0-cogent-biosciences-rises-after-wainwright-raises-pt/
[3] https://www.gurufocus.com/news/2970523/jp-morgan-raises-price-target-for-cogent-biosciences-cogt-cogt-stock-news
[4] https://www.gurufocus.com/news/2963790/agilent-technologies-a-analyst-rating-update-by-evercore-isi-group-a-stock-news
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet